aibioClearmind to issue $1,500,000 in convertible promissory notes
Tickers CMND
The notes carry a $1,500,000 principal amount and a cash purchase price of 90% of principal. The sale falls under an investor agreement amended in April 2026.
Key facts
- Company
- Clearmind Medicine Inc. (NASDAQ: CMND)
- News type
- Debt Financing
- Primary source
- SEC filing
Clearmind Medicine Inc. said in a Form 6-K dated June 1, 2026 that it agreed with a group of investors, called the CLA Investors in the filing, to issue convertible promissory notes with a principal amount of $1,500,000. The aggregate purchase price is payable in cash at 90% of principal, or $1,350,000. The company expects the transaction to close on or about June 1, 2026.
The notes are issued under securities purchase agreements dated September 17, 2025, as amended on April 30, 2026. Under those agreements, the company may sell up to $10,000,000 of promissory notes in total. The filing does not state the interest rate, maturity date, conversion price or security for the new notes, and it does not say what the company will use the proceeds for.
Clearmind is based in Vancouver, British Columbia, and files as a foreign private issuer. The 6-K is signed by Chief Executive Officer Adi Zuloff-Shani. The filing names no placement agent or advisor for the sale.